menu
    • menu
    [{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"Cystathionine beta-synthase (CBS)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.52000000000000002,"dosageForm":"Injection","sponsorNew":"Orphan Technologies \/ Travere Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Travere Therapeutics"},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"OT-58","moa":"Cystathionine beta-synthase (CBS)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orphan Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"Cystathionine beta-synthase (CBS)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.52000000000000002,"dosageForm":"Injection","sponsorNew":"Orphan Technologies \/ Travere Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Travere Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Orphan Technologies

    Menu

    Orphan Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Travere Therapeutics

                            Deal Size : $517.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Retrophin Completes Acquisition of Orphan Technologies, OT-58 Strengthens Pipeline of Therapies Targeting Rare...

                            Details : Orphan Technologies' lead product OT-58 is a novel investigational human enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical homocystinuria.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $90.0 million

                            November 12, 2020

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Travere Therapeutics

                            Deal Size : $517.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Travere Therapeutics

                            Deal Size : $517.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Retrophin Announces Agreement to Acquire Orphan Technologies

                            Details : Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $90.0 million

                            October 22, 2020

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Travere Therapeutics

                            Deal Size : $517.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Orphan Technologies

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orphan Technologies Receives Rare Pediatric Disease Designation from FDA for OT-58

                            Details : Orphan Technologies is now eligible to receive a priority review voucher that may be utilized for subsequent human drug applications.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 26, 2020

                            Lead Product(s) : OT-58

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth